Modulating the Stress Response in Diabetes Mellitus Type 2 Patients Undergoing Colon Surgery

Background Surgical injury provokes a stress response. These pathways mediated by stress hormones and cytokines cause a catabolic state. The loss of body cell mass may result in prolonged convalescence and increased morbidity. Protein catabolism after colorectal surgery is even more increased in patients with type 2 diabetes mellitus. Epidural blockade, by reducing the intensity of the catabolic response, improves substrate utilization after surgery in non-diabetic patients. This effect is even more pronounced in diabetic patients receiving amino acids.

The aim of the study is to explore the effect of two different protocols to manage blood glucose control on glucose and protein metabolism in patients with type 2 diabetes mellitus undergoing colon surgery and receiving epidural analgesia and perioperative feeding with amino acids. The following hypotheses are tested:

1. Tight perioperative blood glucose control with intensified insulin therapy compared to standard blood glucose control in presence of general anesthesia with epidural analgesia and amino acid infusion would reduce endogenous glucose production and leucine oxidation.
2. Tight blood glucose control and perioperative infusion of amino acids induce a more positive protein balance compared to standard blood glucose control by better oxidative glucose utilization and redirecting amino acids from oxidative to synthetic pathways.

Material and Methods A total of 20 patients with diabetes mellitus type 2 undergoing elective colorectal surgery will be admitted to the study. Patients will be randomly assigned to receive standard blood glucose control (blood glucose target <10 mmol*l-1; control group; cytotoxic T lymphocyte (CTL) group, n=8) or to receive tight blood glucose control with intensified insulin therapy (blood glucose target<6 mmol*l-1; intensified insulin group; II group, n=8). All patients will receive general anesthesia and an epidural catheter for perioperative analgesia. During surgery (intraoperative state) and immediately after surgery (postoperative state) when receiving an amino acid infusion protein and glucose kinetics will be assessed using a stable isotope technique with L-[1-13C]leucine and [6,6-2H2]glucose and circulating concentrations of glucose, glucagon, insulin and cortisol will be measured. The primary endpoints of the study will be protein balance. Sample size is set to ensure at least 80% power at a significance level of 0.05.

Study Overview

• Status: Completed
• Conditions: Insulin Resistance; Diabetes Mellitus Type 2
• Intervention / Treatment: Procedure: Intensified insulin therapy

Detailed Description

see information below

• Study Type: Interventional
• Enrollment (Actual): 18
• Phase: Not Applicable

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients undergoing elective colorectal surgery for non-metastatic disease
• Type 2 diabetes mellitus with plasma level of glycosylated hemoglobin level (HbA(1c)) less than 10% indicating normal or moderate glycemic control
• Being capable of signing informed consent
• Accepting an epidural catheter for perioperative analgesia

Exclusion Criteria:

• American Society of Anesthesiologists (ASA) Physical Status classification system 4 with major cardiac disorders (severe arrhythmias, recent myocardial ischemia (MI), heart failure, uncontrolled hypertension)
• Hepatic disorders (liver failure, jaundice, metastatic disease), renal disorders (acute or chronic renal failure or on dialysis)
• Metabolic disorders (untreated hyperthyroidism, pyrexia, more than 10% weight loss over the preceding three months, plasma albumin concentration < 35g/l)
• Anemia (hemoglobin < 10 g/dl)
• Chemotherapy or radiotherapy during six months before surgery
• Inflammatory bowel disease or other inflammatory condition
• Pregnancy
• Previous spine surgery precluding placement of an epidural catheter.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Intensified insulin group; Patients undergoing elective colorectal surgery will receive standard anesthesia including epidural analgesia and nutritional support with an intravenous amino acid solution while receiving tight blood glucose control with intensified insulin therapy (blood glucose target<6 mmol*l-1) via an continuous insulin infusion.	Procedure: Intensified insulin therapy; Other Names: continuous insulin infusion
No Intervention: Control group; Patients undergoing elective colorectal surgery will receive standard anesthesia including epidural analgesia and nutritional support with an intravenous amino acid solution while receiving standard blood glucose control (blood glucose target <10 mmol*l-1) via subcutaneous insulin boluses

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Postoperative protein balance (leucine) (umol/kg/h)	Measured and calculated with a 3-hour stable isotope tracer technique with L-(1-13C)leucine and calorimetry towards the end of the 3 hour period	Postoperative period: starting with arrival in the postoperative care unit and ending after 3 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Intraoperative protein metabolism: Rate of appearance of leucine (umol/kg/h)	Measured and calculated with a 3-hour stable isotope tracer technique with L-(1-13C)leucine	Intraoperative period: starting with the induction of anesthesia and ending after 3 hours (during surgery)
Intraoperative protein metabolism: endogenous rate of appearance of leucine (umol/kg/h)	Measured and calculated with a 3-hour stable isotope tracer technique with L-(1-13C)leucine	Intraoperative period: starting with the induction of anesthesia and ending after 3 hours (during surgery)
Intraoperative glucose metabolism: Endogenous rate of appearance of glucose (umol/kg/min)	Measured and calculated with a 3-hour stable isotope tracer technique with D-(6,6-2H2)glucose	Intraoperative period: starting with the induction of anesthesia and ending after 3 hours (during surgery)
Intraoperative glucose metabolism: Glucose clearance (ml/kg/min)	Measured and calculated with a 3-hour stable isotope tracer technique with D-(6,6-2H2)glucose and plasma glucose measurement	Intraoperative period: starting with the induction of anesthesia and ending after 3 hours (during surgery)
Postoperative protein metabolism: Rate of appearance of leucine (umol/kg/h)	Measured and calculated with a 3-hour stable isotope tracer technique with L-(1-13C)leucine and calorimetry towards the end of the 3 hour period	Postoperative period: starting with arrival in the postoperative care unit and ending after 3 hours
Postoperative protein metabolism: Endogenous rate of appearance of leucine (umol/kg/h)	Measured and calculated with a 3-hour stable isotope tracer technique with L-(1-13C)leucine and calorimetry towards the end of the 3 hour period	Postoperative period: starting with arrival in the postoperative care unit and ending after 3 hours
Postoperative protein metabolism: Leucine oxidation (umol/kg/h)	Measured and calculated with a 3-hour stable isotope tracer technique with L-(1-13C)leucine and calorimetry towards the end of the 3 hour period	Postoperative period: starting with arrival in the postoperative care unit and ending after 3 hours
Postoperative protein metabolism: Protein synthesis (leucine) (umol/kg/h)	Measured and calculated with a 3-hour stable isotope tracer technique with L-(1-13C)leucine and calorimetry towards the end of the 3 hour period	Postoperative period: starting with arrival in the postoperative care unit and ending after 3 hours
Postoperative glucose metabolism: Endogenous rate of appearance of glucose (umol/kg/min)	Measured and calculated with a 3-hour stable isotope tracer technique with D-(6,6-2H2)glucose	Postoperative period: starting with arrival in the postoperative care unit and ending after 3 hours
Postoperative glucose metabolism: Glucose clearance (ml/kg/min)	Measured and calculated with a 3-hour stable isotope tracer technique with D-(6,6-2H2)glucose and plasma glucose measurement	Postoperative period: starting with arrival in the postoperative care unit and ending after 3 hours

Collaborators and Investigators

• Sponsor: University Hospital, Basel, Switzerland
• Investigators: Study Chair: Andrea Kopp Lugli, MD, MSc, University Hospital, Basel, Switzerland

Study record dates

Study Major Dates

• Study Start: December 1, 2009
• Primary Completion (Actual): November 1, 2010
• Study Completion (Actual): November 1, 2010

Study Registration Dates

• First Submitted: August 8, 2016
• First Submitted That Met QC Criteria: August 8, 2016
• First Posted (Estimate): August 11, 2016

Study Record Updates

• Last Update Posted (Estimate): August 11, 2016
• Last Update Submitted That Met QC Criteria: August 8, 2016
• Last Verified: August 1, 2016

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Hyperinsulinism; Diabetes Mellitus; Diabetes Mellitus, Type 2; Insulin Resistance; Hypoglycemic Agents; Physiological Effects of Drugs; Insulin; Insulin, Globin Zinc
• Other Study ID Numbers: 230/09